ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

ProMIS Neurosciences (PMN) announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its lead drug candidate, PMN310, designed for the treatment of Alzheimer’s disease. The dosing of several patients marks an important milestone in assessing the safety, tolerability, and pharmacokinetics of PMN310 and underscores ProMIS’s commitment to addressing the urgent need for targeted therapies in AD by selectively targeting toxic oligomers, which we believe to be a key driver of disease progression. PMN310 is a humanized monoclonal antibody designed and developed to selectively target only soluble amyloid-beta oligomers, which are believed to be the most toxic and pathogenic form of Abeta, while avoiding any binding to Abeta monomers and amyloid plaques.